3xTG-AD Triple Transgenic Mouse Model
Overview
Mermaid diagram (expand to render)
The 3xTG-AD mouse model is a triple transgenic mouse model of Alzheimer's disease developed by Oddo et al. in 2003[@oddo2003]. It expresses three mutant genes associated with familial AD: [APP](/genes/app) Swedish (KM670/671NL), [MAPT](/genes/mapt) P301L, and [PSEN1](/genes/psen1) M146V. This model is unique in that it develops both amyloid-beta (Abeta) plaques and neurofibrillary tangles (NFTs), making it one of the most valuable tools for studying AD pathogenesis and the interaction between the two hallmark pathologies["@laferla2012"].
The temporal progression of pathology in 3xTG-AD roughly mirrors human disease: Abeta deposits appear first (by 6 months), followed by tau pathology (by 12-15 months), then cognitive decline. This makes the model particularly valuable for studying disease mechanisms and testing therapeutic interventions that target both pathologies["@oddo2003a"].
Genetic Background
Transgene Construction
The 3xTG-AD model contains three human transgenes under neuron-specific Thy1.2 promoter control[@oddo2003]:
| Gene | Mutation | Effect |
|------|----------|--------|
| [APP](/genes/app) | Swedish (K670N/M671L) | 3-4× increased Aβ production |
| [MAPT](/genes/mapt) | P301L | Tau hyperphosphorylation and aggregation |
| [PSEN1](/genes/psen1) | M146V (knock-in) | Enhanced Aβ42/Aβ40 ratio |
APP Swedish Mutation
The Swedish double mutation (K670N/M671L) is located at the β-secretase cleavage site in [APP](/genes/app). It dramatically increases amyloid-beta production, particularly the more aggregation-prone Aβ₁₋₄₂ species[@oddo2003]. The Thy1.2 promoter drives neuron-specific expression, resulting in Aβ accumulation primarily in the brain.
MAPT P301L Mutation
The [MAPT](/genes/mapt) P301L mutation, associated with frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), promotes hyperphosphorylation and aggregation of tau by reducing microtubule binding affinity. Tau pathology develops progressively with age, first in the hippocampus and then spreading to cortical regions[@oddo2004].
PSEN1 M146V Knock-in
The [PSEN1](/genes/psen1) M146V mutation is knocked into the endogenous mouse Psen1 locus, ensuring physiologically appropriate expression levels. This enhances γ-secretase activity, shifting APP processing toward Aβ42 production[@laferla2012].
Background Strain
- Strain: C57BL6/129S mixed background
- Expression: Neuron-specific via Thy1.2 promoter
- Integration: Chromosome integration at unknown locus
Phenotype Characteristics
Amyloid-Beta Plaques
- Onset: 6 months of age[@oddo2004]
- Location: Cortex and hippocampus (subiculum first)
- Type: Mixed Aβ40 and Aβ42, with Aβ42 predominating
- Progression: Increases dramatically with age; by 12 months, extensive plaque burden
The amyloid pathology follows a defined temporal pattern. Diffuse Aβ deposits appear at 6 months in the subiculum and cortex. By 12 months, plaque density increases significantly throughout the hippocampus and cortex[@oddo2004].
Neurofibrillary Tangles
- Onset: 12-15 months of age
- Location: Hippocampus and cortex
- Form: Hyperphosphorylated tau aggregates at multiple epitopes (AT8, AT180, PHF-1)
Tau pathology develops after Aβ pathology, consistent with the amyloid cascade hypothesis. The P301L mutation promotes aggregation, but true neurofibrillary tangles are limited by species differences in tau sequence. The model shows phosphorylated tau at AT8 (Ser202/Thr205), AT180 (Thr231), and PHF-1 (Ser396/404)[@hansson2019].
Synaptic Deficits
Synaptic dysfunction is one of the earliest measurable deficits in the 3xTG-AD model[@singh2015]:
- Early onset: Impaired long-term potentiation (LTP) in hippocampal CA1 by 3-4 months — before plaques or tangles appear
- Structural changes: Reduced dendritic spine density
- Mechanism: Soluble Aβ oligomers accumulate intracellularly and disrupt synaptic function[@billings2005]
Behavioral Phenotype
- Spatial memory: Impaired in Morris water maze by 6 months[@gimenez2009]
- Working memory: Deficits in Y-maze tasks by 9 months
- Anxiety-like behavior: Changes in elevated plus-maze
- Progressive decline: Worsens with age
Neuroinflammation
Microglial Activation
The 3xTG-AD model exhibits robust neuroinflammation, with microglial activation accompanying Aβ and tau pathology. Activated microglia cluster around Aβ plaques, adopting a disease-associated microglia (DAM) phenotype. These microglia attempt to clear Aβ through phagocytosis but may become dysfunctional, contributing to chronic inflammation[@le2014].
Microglial activation can be detected via Iba1 immunohistochemistry, with increased staining density around plaques and in regions of tau pathology. The inflammatory response includes production of cytokines such as IL-1β, TNF-α, and IL-6.
Astrocytosis
Reactive astrocytes are prominent in the 3xTG-AD model. GFAP-positive astrocytes show hypertrophy and increased proliferation in response to neuropathology. Astrocytic responses include both potentially beneficial functions (Aβ sequestration, neurotrophic support) and detrimental effects (excitotoxicity, inflammatory mediator release)[@rodriguez2013].
Mitochondrial Abnormalities
The 3xTG-AD model demonstrates significant mitochondrial dysfunction. Proteomic studies have identified altered expression of mitochondrial proteins involved in energy metabolism, oxidative phosphorylation, and antioxidant defenses. Complex I and IV activity is reduced in aged mice, leading to impaired ATP production[@perez2005].
In vivo imaging studies have demonstrated cerebral glucose hypometabolism in the 3xTG-AD model, similar to patterns observed in human AD patients. PET imaging using fluorodeoxyglucose (FDG) shows reduced glucose uptake in the hippocampus and cortex that correlates with cognitive deficits[@yang2018].
Autophagy and Proteostasis
Autophagy is impaired in the 3xTG-AD model, with accumulation of autophagic vacuoles in neurons. This impairment affects clearance of both Aβ and tau, contributing to protein aggregation. The mTOR pathway shows dysregulation, and restore of autophagy through pharmacological approaches has shown promise in reducing pathology[@zhang2019].
Research Applications
Therapeutic Testing
The 3xTG-AD model is widely used to test[@laferla2012]:
Anti-amyloid therapies: Immunotherapies (anti-Aβ antibodies), secretase modulators
Anti-tau therapies: Tau aggregation inhibitors, kinase inhibitors, immunotherapy
Combination approaches: Simultaneous Aβ and tau targeting
Disease-modifying interventions: Testing interventions that modify disease progressionDisease Mechanism Studies
- Amyloid-tau interaction: Cross-seeding and templated propagation studies[@pooler2012]
- Temporal relationships: Determining which pathology drives progression
- Synaptic dysfunction: Early events preceding visible pathology
- Propagation mechanisms: Spreading of pathology through neural circuits
Biomarker Development
- Fluid biomarkers: CSF Aβ and tau correlation with brain pathology
- Imaging biomarkers: PET amyloid and tau binding
- Behavioral correlations: Test performance correlates with neuropathology
Comparison with Other AD Models
| Feature | 3xTG-AD | 5xFAD | APP/PS1 | Tg2576 |
|---------|---------|-------|---------|--------|
| Amyloid plaques | Yes (6 mo) | Yes (2 mo) | Yes (6-9 mo) | Yes (9-12 mo) |
| Neurofibrillary tangles | Yes (12 mo) | Minimal | No | No |
| Dual pathology | Yes | No | No | No |
| Cognitive deficits | 6-12 months | 4-6 months | 8-12 months | 12-15 months |
| Cross-seeding studies | Unique value | No | No | No |
Strengths and Limitations
Strengths
- Dual pathology: Both Aβ and tau pathology in one model — unique among AD mouse models
- Age-dependent progression: Clear temporal progression of pathologies matching human disease
- Early synaptic dysfunction: Measurable deficits before visible pathology
- Cross-seeding studies: Unique ability to study Aβ-tau interactions[@pooler2012]
- Comprehensive platform: Suitable for combination therapy testing
Limitations
- Strain variability: Genetic background affects phenotype expression
- Non-physiological expression: Thy1.2 promoter drives higher than normal transgene levels
- Tau pathology: Less robust neurofibrillary tangles than in human AD — mouse tau does not form true human-style NFTs
- Translation concerns: Murine model cannot fully replicate human AD
- Glial differences: Murine glial responses may differ from human
Experimental Protocols
Recommended Behavioral Battery
- Morris water maze: Spatial learning and memory (6+ months)
- Y-maze: Working memory (6+ months)
- Elevated plus-maze: Anxiety-like behavior
- Novel object recognition: Episodic memory
- Contextual fear conditioning: Associative learning
Histological Protocols
| Target | Markers |
|--------|---------|
| Aβ plaques | 6E10, 4G8, Thioflavin S |
| Tau pathology | AT8, AT180, PHF-1, MC1 |
| Microglia | Iba1, CD68 |
| Astrocytes | GFAP |
| Synapses | Synaptophysin, PSD-95 |
Key Publications
[Oddo et al., Triple-transgenic model of AD with plaques and tangles (2003)](https://pubmed.ncbi.nlm.nih.gov/14583111/)[@oddo2003]
[Oddo et al., Amyloid deposition precedes tangle formation (2003)](https://pubmed.ncbi.nlm.nih.gov/14592797/)[@oddo2003a]
[LaFerla & Green, Animal models of Alzheimer disease (2012)](https://pubmed.ncbi.nlm.nih.gov/22239541/)[@laferla2012]
[Oddo et al., Dynamic changes in Aβ and tau pathology (2004)](https://pubmed.ncbi.nlm.nih.gov/15456810/)[@oddo2004]
[Billings et al., Intraneuronal Aβ causes early cognitive deficits (2005)](https://pubmed.ncbi.nlm.nih.gov/15768841/)[@billings2005]
[Giménez-Llort et al., Modeling key features of AD in 3xTG-AD mice (2009)](https://pubmed.ncbi.nlm.nih.gov/20169042/)[@gimenez2009]
[Hansson et al., Tau pathology and neurodegeneration in 3xTG-AD (2019)](https://pubmed.ncbi.nlm.nih.gov/30387133/)[@hansson2019]
[Pooler et al., Amyloid accelerates tau propagation (2012)](https://pubmed.ncbi.nlm.nih.gov/23283334/)[@pooler2012]
[Le et al., Neuroinflammation in the 3xTG-AD model (2014)](https://pubmed.ncbi.nlm.nih.gov/25266697/)[@le2014]
[Rodriguez et al., Glial responses in the 3xTG-AD model (2013)](https://pubmed.ncbi.nlm.nih.gov/23178265/)[@rodriguez2013]Cross-Links
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [5xFAD Mouse Model](/models/5xfad-mouse)
- [APP Gene](/genes/app)
- [MAPT Protein](/genes/mapt)
- [PSEN1 Gene](/genes/psen1)
- [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade-hypothesis)
- [Tau Pathology in Neurodegeneration](/mechanisms/tau-pathology-neurodegeneration)
- [Neuroinflammation in AD](/mechanisms/neuroinflammation-alzheimers)
- [MPTP Mouse Model (PD reference)](/models/mptp-mouse-model-parkinsons)